Monoclonal Antibodies: A Promising Treatment for Lymphoma

The video discusses a trial for a new lymphoma treatment using Madthera, a monoclonal antibody. This drug targets and attacks cancer cells by binding to CD20 proteins on their surface. The treatment is administered weekly over four weeks, with the first session requiring hospital observation. Madthera's mechanism involves targeting CD20 proteins found on pre B&B lymphocytes, leading to the death of tumor cells.

What is the primary method of administering Madthera to patients?

• Oral tablets

• Intravenous infusion

• Inhalation

• Topical application

After the first session of Madthera treatment, what is the next step for patients?

• They stay in the hospital for observation

• They receive a different medication

• They undergo surgery

• They are discharged immediately

Which proteins does Madthera target once inside the body?

• CD21 proteins

• CD22 proteins

• CD20 proteins

• CD19 proteins

Where are the CD20 expressing target cells primarily located?

• In the heart and lungs

• In the peripheral blood, bone marrow, and lymph nodes

• In the liver and kidneys

• In the skin and muscles

What is the result of Madthera binding to CD20 cell surface proteins?

• Cell division

• Cell mutation

• Increased cell growth

• Tumor cell death